#United States #Irvine #Henlius #T-Cell Engagers #Amberstone

Amberstone Biosciences Partners with Henlius for Cancer Treatment

Amberstone Biosciences, a preclinical-stage oncology company, recently announced a significant collaboration with Shanghai Henlius Biotech, a commercial-stage biopharmaceutical entity. The partnership centers around developing conditionally activated T-cell engagers (TCEs) that target solid tumors, a crucial advancement in cancer therapy.

Overview of the Collaboration

The agreement permits Amberstone to utilize its proprietary T-MATE™ (Tumor Microenvironment Activated Therapeutics) platform technology, creating promising preclinical candidates for up to two targets identified by Henlius. Importantly, Henlius will spearhead all subsequent research, development, and commercialization efforts concerning these targets globally.

One of the notable challenges in T-cell engager development for solid tumors is the risk of cytokine release syndrome and toxicities affecting healthy tissues. Amberstone's T-MATE technology addresses these risks by using a reversible pH gating mechanism. This ensures that T-cell activation is minimized in healthy tissues while ensuring powerful therapeutic activity in the acidic pH commonly found in tumor microenvironments. Preclinical studies have demonstrated robust tumor-cell destruction in conditions that mimic those of actual tumors, with significantly reduced activity under normal physiological pH conditions.

Amberstone is set to progress its leading T-MATE TCE asset into clinical development by mid-2027, indicating a potential pathway towards innovative cancer therapies.

Financial Aspects of the Agreement

Under the terms of this collaboration, Amberstone will receive an upfront payment as well as research funding. Additionally, the company is positioned to earn up to $440 million in potential development, regulatory, and sales milestone payments for each target, alongside tiered royalties on net sales, further enhancing the financial viability of their career in cancer research.

About Amberstone Biosciences

Founded in Irvine, California, Amberstone Biosciences is dedicated to pioneering tumor-activated therapies through both internal innovation and meaningful partnerships. The T-MATE platform exemplifies their commitment to enhancing the therapeutic window of T-cell engagers, ensuring minimal activity in blood and normal tissues while maintaining efficacy within the tumor microenvironment. Their lead candidate is in the IND-enabling phase of development, while new programs are continuously being explored internally.

About Henlius

Established in 2010, Shanghai Henlius Biotech operates as a global, innovation-driven biopharmaceutical company devoted to supplying high-quality, cost-effective biologic therapies. With a comprehensive platform that spans research and development to commercialization, the company boasts a portfolio of ten products that have secured regulatory approvals across over 60 countries, including approvals from the U.S. FDA and European Commission. Henlius is also navigating a robust pipeline of early-stage assets and operates a biologics manufacturing network that boasts a substantial total capacity, showcasing its capability in the biopharmaceutical sector.

Looking Ahead

The collaboration between Amberstone and Henlius signifies a pivotal step in the domain of oncology, focusing on significantly improving T-cell therapies for solid tumors. Provided the effective implementation and execution of their strategy, these innovations could pave the way for new treatments that many patients have been waiting for in their battles against cancer. Both companies are poised to make a lasting impact on the future of cancer therapy, highlighting the importance of collaborative efforts in medical innovation.